2024-516969-36-00招募中2 期
A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- The primary endpoint parameters are occurrence of AEs/SAEs, vital signs, physical examination, ECG, and the results of urinalysis and safety laboratory tests (haematology, electrolytes, liver function, and biochemistry including S/P-Creatinine and S/P-Cystatin C). Note that the primary endpoints will be used to confirm the safety and tolerability of ODX in the patient population and no statistical testing will be performed for these endpoints.
研究概览
简要总结
• To determine the safety and tolerability of ODX in subjects with relapsed/refractory multiple myeloma.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Subject (male or female) is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- •Documented diagnosis av multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria.
- •Measurable disease defined as either: • Serum monoclonal paraprotein (M-protein) level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or • Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
- •Subjects must have received 1-5 prior lines of any therapy
- •Subjects must have documented evidence of progressive disease based on the IMWG criteria on or after their last line of therapy.
- •Performance status ECOG 0-2
- •Laboratory requirements: Haematology: Neutrophils ≥ 1.0 x 109/l Hemoglobin ≥ 80 g/l Platelets ≥ 50 x 109/l Hepatic function: Total S/P-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN Renal function: S/P-creatinine ≤ 1.5 times ULN Electrolytes: S/P-sodium, S/P-potassium, S/P-calcium corrected for S/P albumin , S/P-phosphate, and S/P magnesium, all within normal ranges. At the discretion of the Investigator, supplements may be given to correct these values, in which case electrolytes must be shown to be within normal ranges before inclusion into the study.
- •No evidence (< 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin).
- •Able to adhere to the study visit schedule and other protocol requirements.
排除标准
- •Concurrent use of other anti-cancer agents/treatments.
- •Any treatment modalities involving chemotherapy, radiation, or major surgery within 4 weeks prior to treatment in this study.
- •Simultaneous participation in any other study involving investigational drugs or having participated in an investigational study less than 4 weeks prior to start of study treatment.
- •Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he or she participates in the study.
- •Known active CNS involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
- •Plasma cell leukemia, Waldenstrom’s macroglobulinemia or POEMS syndrome.
- •Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug.
- •Treatment with bisphosphonates or denosumab within 6 weeks prior to first dose of study medication.
- •Male subjects not willing to use condom to prevent pregnancy and drug exposure of a fertile female partner and refrain from donating sperm from the date of the first dose until the end of study treatment.
- •Pregnant or breastfeeding females.
- •Female subjects of childbearing potential* not willing to use a contraceptive method with a failure rate of < 1% to prevent pregnancy during study treatment. Highly effective birth control methods include: • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: o oral o intravaginal o transdermal • progestogen-only hormonal contraception associated with inhibition of ovulation: o oral o injectable o implantable • intrauterine device • intrauterine hormone-releasing system (for example, progestin-releasing coil) • vasectomized male (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate) • bilateral tubal occlusion or hysterectomy. *Female subjects are considered of non-childbearing potential if they are pre-menopausal females with a documented tubal ligation or hysterectomy or bilateral oophorectomy; or as post-menopausal females defined as at least 12 months of amenorrhea.
- •Subjects in which pre-medication with dexamethasone, antihistamine, and paracetamol would be contraindicated.
结局指标
主要结局
The primary endpoint parameters are occurrence of AEs/SAEs, vital signs, physical examination, ECG, and the results of urinalysis and safety laboratory tests (haematology, electrolytes, liver function, and biochemistry including S/P-Creatinine and S/P-Cystatin C). Note that the primary endpoints will be used to confirm the safety and tolerability of ODX in the patient population and no statistical testing will be performed for these endpoints.
The primary endpoint parameters are occurrence of AEs/SAEs, vital signs, physical examination, ECG, and the results of urinalysis and safety laboratory tests (haematology, electrolytes, liver function, and biochemistry including S/P-Creatinine and S/P-Cystatin C). Note that the primary endpoints will be used to confirm the safety and tolerability of ODX in the patient population and no statistical testing will be performed for these endpoints.
次要结局
- • Best overall response rate (partial response [PR] or better) reached during the 14-week treatment/follow-up period, as measured by the IMWG response criteria.• Change in the levels of the serum biomarkers M-protein, FLC, CTX, osteocalcin, and bone-specific S ALP from baseline to Weeks 2, 4, 6, 8, 10, 12, and 14.• Quality of Life (QoL) scores, as measured by the EQ-5D-5L assessment tool, from baseline to Weeks 2, 8, and 14
研究者
Anders Holmberg
Scientific
Dextech Medical AB
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of International Prognostic Index (IPI) High or High-Intermediate Risk - R-CODOX-M/IVACEUCTR2005-003479-19-GBniversity College London150
进行中（未招募）
3 期
Study of Dato-DXd Versus Standard Chemotherapy in patient with Inoperable or MetastaticHormone Receptor-Positive, HER2-Negative Breast Cancer who has been failed on previous chemotherapyCTRI/2022/03/040959ASTRAZENECA AB
招募中
1 期
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast CancerInoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic ChemotherapyMedDRA version: 23.0Level: PTClassification code: 10083232Term: HER2 negative breast cancer Class: 100000004864CTIS2023-509631-37-00AstraZeneca AB697
招募中
3 期
A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator*s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)HER2-Negative Breast Cancer/ Breastcancer that cannot be removed by surgery or has spread to other parts of your bodyInoperable or Metastatic Hormone Receptor-Positive10006291NL-OMON52270Astra Zeneca18
进行中（未招募）
1 期
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast CancerEUCTR2020-005620-12-ESAstraZeneca AB700